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Introduction
Brucella is a genus of bacteria belonging to the phy-
lum Proteobacteria, class Alphaproteobacteria, order 
Rhizobiales, family Brucellaceae. Alphaproteobacteria 
is a very diverse group as to this class belongs both, the 
pathogens associated with plants: Agrobacterium spp., 
Sinorhizobium spp., Mesorhizobium spp. and the patho-
gens, which cause dangerous infections of animals, e.g. 
Ricketsia spp., Bartonella spp., Brucella spp. and many 
others (Dwight and Bowman, 2011). 
Brucella genus is responsible for brucellosis, a severe 
febrile disease. Brucellosis is a worldwide problem, 
causing abortion and infertility in domestic and wild 
animals (Lapaque et al., 2005). Infection factors are 
aerobic, small, Gram-negative rods. Brucella, a genus 
discovered in 1887 by David Bruce, contains the follow-
ing species: Brucella suis, Brucella ovis, Brucella abortus, 
Brucella canis, Brucella melitensis, Brucella neotomae, 
Brucella ceti, Brucella pinnipedialis, Brucella microti, 
Brucella inopinata, Brucella papionis, Brucella vulpis and 
other strains without standing in nomenclature, that 
include environmental samples (Galińska and Zagór-
ski, 2013; Whatmore et al., 2014; Scholz et al., 2016). 
Some species contain biovars, for example: B. suis have 
five biovars, B. melitensis contain three and B. abortus 
– nine biovars (Mizak et al., 2014). Most of these species 
infect mainly specific hosts. B. abortus causes disease in 
cattle and infections usually lead to abortion; whereas 
B. suis is responsible for brucellosis in pigs, resulting in 
reproductive problems. Sheep are hosts for B. melitensis; 
infection causes impaired fertility. B. ovis is an etiologi-
cal factor in sterility of rams (Megid et al., 2010). Cur-
rently, about 500 000 cases of human brucellosis have 
been reported worldwide annually (Byndloss and Tsolis, 
2016). Brucellosis is an endemic zoonosis with infection 
predominantly occurring in Middle East, Mediterra-
nean rim (Portugal, Spain, Greece), Asia, Africa, South 
and Central America where the intake of dairy products 
is high, and protection of animal health is insufficient 
(Rubach et al., 2013). There are single cases reported in 
Poland, however connected with occupational exposure 
or with traveling to Mediterranean countries (Galińska 
and Zagórski, 2013). B. abortus and B. suis are isolated 
not only from livestock but also from different wild-
life species (bears, buffalo, bison, caribu, camelids, elk, 
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A b s t r a c t
Brucellae are Gram-negative, small rods infecting mammals and capable of causing disease called brucellosis. The infection results in 
abortion and sterility in domestic animals (sheeps, pigs, rams etc). Especially dangerous for humans are: Brucella melitensis, Brucella suis, 
Brucella abortus, and Brucella canis that trigger unspecific symptoms (flu-like manifestation). Brucella rods are introduced via host cells, by 
inhalation, skin abrasions, ingestion or mucosal membranes. The most important feature of Brucella is the ability to survive and multiply 
within both phagocytic and non-phagocytic cells. Brucella does not produce classical virulence factors: exotoxin, cytolisins, exoenzymes, 
plasmids, fimbria, and drug resistant forms. Major virulence factors are: lipopolysaccharide (LPS), T4SS secretion system and BvrR/BvrS 
system, which allow interaction with host cell surface, formation of an early, late BCV (Brucella Containing Vacuole) and interaction with 
endoplasmic reticulum (ER) when the bacteria multiply. The treatment of brucellosis is based on two-drug therapy, the most common 
combinations of antibiotics are: doxycycline with rifampicin or fluoroquinolones with rifampicin. Currently, also other methods are used 
to disrupt Brucella intracellular replication (tauroursodeoxycholic acid or ginseng saponin fraction A).
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ferrets, deer, foxes, rodents, rabbits, wolves) and marine 
mammals (dolphins, dugongs, manatees, otters, sea 
porpoise) (Coelho et al., 2015). B. melitensis is rarely 
encountered in wildlife, nonetheless individual cases 
have been reported in ibex and in chamois in Alps. 
B. ovis and B. canis have not been detected in wildlife 
in Europe up to date. B. pinnipedialis and B. ceti cause 
the most common infections in marine mammals. Birds 
are resistant to Brucella infection, whereas fish seem to 
be susceptible to B. pinnipedialis and B. ceti infections 
(Godfroid et al., 2013). Infection is transmitted through 
close contact and during a common pasture. 
Brucellosis is transferred from animals to humans, 
frequently human to human transmission occurs 
(Osman et al., 2016). Especially dangerous for humans 
are: B. melitensis, B. suis, and B. abortus, B. canis. Brucel-
losis in human presents with symptoms like influenza: 
undulating fever, depression, weight loss, hepatomegaly, 
and splenomegaly (Bingöl et al., 1999). Mainly human 
cases are connected to occupational risk or consumption 
of unprocessed dairy products (Boschiroli et al., 2001; 
de Figureido et al., 2015). Brucella rods can enter via host 
cells by inhalation, ingestion, skin abrasion, or mucosal 
membranes (Franco et al., 2007). After penetration into 
host, rods multiply in lymph nodes; afterward, they pen-
etrate other organs (Galińska and Zagórski, 2013). Bru­
cella, can modify immune response in host cells; it has 
an affinity to the cells of specific tissues, e.g. placental 
trophoblast in fetal lung, pregnant females or reproduc-
tive system (de Figureido et al., 2015). Brucellosis causes 
enlargement of lymph nodes, liver and spleen (Perkins 
et al., 2010). Pathogenicity of Brucella is dependent on 
their ability to multiply and survive within macrophages 
(Sangari and Agűero, 1996; Christopher et al., 2010).
Characteristics of Brucella
Species of the genus Brucella belong to small cocco-
bacilli, measuring about 0,6–1,5 µm (Alton and Forsyth, 
1996). They occur in single forms; rarely they create 
pairs or chains (Mizak et al., 2014). Brucella are non-
spore forming and non-motile Gram-negative coco-
bacilli (GNCB) (Alton and Forsyth, 1996). Brucella is 
an intracellular pathogen, during an infection it sur-
vives and multiplies in macrophages; the bacteria adapt 
to the acidic pH, low levels of oxygen, and low levels of 
nutrients (Kőhler et al., 2002). 
Lipopolisaccharide (LPS) is an essential element 
of structure building in each Gram-negative bacterial 
cell. Brucella is a genus that creates two forms of LPS. 
The smooth forms present complete LPS in the outer 
membrane, the rooth phenotype does not contain poli-
saccharide O-chain (Lapaque et al., 2005; Seleem et al., 
2008). These infectious agents are able to produce cyto-
chrome oxidase, catalase, and most of them are able to 
hydrolyze urea (Iowa State University, 2009). Brucella 
does not produce classical pathogenic factors, such as: 
exotoxin, cytolisins, exoensymes, exoproteins, capsules, 
plasmids, fimbria, and drug resistant forms (Seleem 
et al., 2008; Baldi and Giambartolomei, 2013; Tan et al., 
2015). Bacterial cells are able to survive for a prolonged 
time in water, aborted fetus, soil, dairy products, meat, 
dung, and dust (Gwida et al., 2010). For isolation of 
Brucella spp. the enrichment and selective media such 
as Thayer-Martin’s medium or Farrell’s medium are 
commonly used. The colonies mature after four to six 
days of incubation at temperature of 37°C. They can also 
grow at 28°C, but poorly and slowly. Moreover, these 
bacteria can grow in both aerobic atmosphere and in 
10% CO2; while, their growth is enhanced without addi-
tional CO2 on a serum dextrose agar (Iowa State Univer-
sity, 2009; Whatmore et al., 2014; Gupte and Kaur, 2015). 
A wide range of bacterial detection methods is 
available. The predominatingly used culture media 
are: Bacto Tryptose (Difco), Triptcase soy (BBL), Tryp-
tone soya (Oxoid), Triptic soy (Gibco). For culture of 
blood or body fluid a biphase medium called Castaneda 
should be used. Castaneda consists of two phases: liq-
uid and solid closed in bottle. Liquid medium contains 
1–2% of sodium citrate. Sample (5–10 ml) is added to 
the medium and incubated in 37°C in perpendiculary 
standing bottle in 10% carbon dioxide atmosphere 
(Gupte and Kaur, 2015). Serological tests are used to 
detect infection by examination of a specific antibodies 
level in serum. In the first week of Brucella infection 
the titres of IgM are dominant, but in the second week 
IgG class is prevalent. After four weeks, both types of 
antibodies reach a peak; durable, high titres of IgG can 
evidence failure in treatment (Al Dahouk et al., 2013). 
Serum Agglutination Test (SAT) and Enzyme linked 
immunosorbent assay (ELISA) are the most common 
serological tests used for diagnosis of brucellosis. SAT 
is based on a survey of agglutination titer of different 
serum dilution against Brucella cell suspension (Alshaa-
lan et al., 2014). ELISA depends on detection of anti-
bodies against the antigen – smooth LPS in serum 
(Gerasu and Kassa, 2016). The most effective methods 
for detection of brucellosis are molecular techniques 
(classical PCR, real-time PCR). The PCR method 
applies various pairs of primers to amplify different 
fragments of the genome. The examples of genes used 
to identification of Brucella spp. are: BCSP 31 (primers: 
B4/B5), sequence of 16S rRNA (primers: F4/R2), omp2 
gene (primers: JPF/JPR) (Baddour and Alkhalifa, 2008).
Virulence factors
Lipopolisaccharide. LPS is an essential virulence 
factor of Brucella. LPS consists of lipid A, oligosaccha-
ride core and O-antigen in Gram-negative bacteria. 
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Lipopolisaccharide is different and non-classical in 
Brucella as compared to other Gram-negative bacte-
ria, for example E. coli (Cardosos et al., 2006; Chris-
topher et al., 2010). Lipopolisaccharide from Brucella 
strains is less toxic and less active than the classical 
LPS isolated from E. coli. Classical LPS causes a high 
pyrogenicity, while non-classical LPS shows low pyro-
genicity, being a weak inducer of tumor necrosis factor 
(Christopher et al., 2010). Three features distinguish-
ing it from other Gram-negatives characterize lipid A 
found in B. abortus: i) the fundamental component is 
diaminoglucose instead glucosamine, ii) longer acyl 
groups, and iii) lipid A is connected to the core by 
amide bonds, instead ester and amide bounds (Lapaque 
et al., 2005). In strains with smooth colonies, the 
smooth LPS, (S-LPS) contains: i) lipid A, that consists 
of two types of aminoglycose, and fatty acid besides 
β-hydroxymiristic acid, ii) core comprises mannose, 
glucose, quinovosamine, and iii) O-chains are compo-
sed of 4-formamido-4,6-dideoxymannose. The struc - 
ture of the R-LPS in strains with rough colonies is 
similar to the S-LPS, except for O-chains, which are 
reduced or absent (Corbel, 1997). B. suis has S-LPS. The 
O-chain connects with lipid rafts on the macrophage 
surface and the bacteria enter the cell. Brucella strains 
with R-LPS, for example B. ovis or B. canis do not con-
nect with lipid rafts and rapidly connect with lysosomes 
(Lapaque et al., 2005). The strains with S-LPS are able 
to restrain host cell apoptosis by the interaction of the 
O-chain with TNF-α (tumor necrosis factor). Thus, 
dead cells do not release specific factors, therefore they 
do not activate the immune system and Brucellae are 
able to avoid host immune surveillance (Fernandez- 
-Prada et al., 2003).
Type IV secretion system (T4SS). T4SS is a multi-
protein complex and participates in secretion of bacte-
rial macromolecues (Cascales and Christie, 2003). This 
system is typified by virB operon encoding 12 proteins 
(11 860 bp) and exhibits in Brucella spp. with a high 
degree of similarity to T4SSs found in rhizobia, for 
example in phytopatogenic Agrobacterium tumefa­
ciens (O’Callaghan et al., 1999). Expression of the virB 
operon is regulated by the regulator of quorum-sensing 
– VjbR (Seleem et al., 2008). The wild strains of Brucella 
are able to multiply only in the endoplasmic reticulum. 
VirB mutants of Brucella spp. are unable to multiply 
within the endoplasmic reticulum, it can result from the 
incapability to reach the ER, or multiply within (Delure 
et al., 2001). In macrophages, rods of Brucella spp. are 
localized in Brucella-containing vacuole (BCV); this 
organelle interacts with the ER and is responsible for 
formation of specialized brucellae-multiplication com-
partment (Kőhler et al., 2002). The acquisition of endo-
plasmic reticulum membrane depends on a functional 
virB secretion system – T4SS (Celli et al., 2003).
Superoxide dismutase and catalase. Macrophages 
with Brucella produce reactive oxygen intermediates 
(ROIs), this is a primary mechanism of destruction of 
the bacteria ingested, and it also prevents their intracel-
lular replication (Gee et al., 2005; Seleem et al., 2008). 
The following ROIs: O2– (superoxide), H2O2 (hydrogen 
peroxide), OH– (hydroxyl radical) are very detrimen-
tal for cell structure. The production of enzymes is 
the main line of defense, counteracting reactive oxy-
gen intermediates. These enzymes include superoxide 
dismutase (SOD) and catalase (Gee et al., 2005). SOD 
(metalloenzyme) is encoded by sod sequence. An 
enzyme contains iron, magnesium, or zinc and cop-
per at its active site (Benov and Fridovich, 1994). SOD 
is responsible for dismutation of O2– (superoxide) to 
H2O2 (hydrogen peroxide) and O2 (oxygen) – transfer 
from one molecule to another (2O2–+2H+ →H2O2 + O2) 
(Gopal and Elumalai, 2017). Some species possess two 
types of SOD (B. abortus, B. melitensis, B. suis). The first 
is cytoplasmic – a Mn cofactor – SodA. SodA neutral-
izes endogenously generated O2– – product of aerobic 
metabolism. The second one, SodC is periplasmic Cu, 
Zn-SOD, an enzyme responsible for neutralizing exo-
genously generated O2– and protection from the res-
piratory burst within macrophages (Beck et al., 1990, 
Seleem et al., 2008, Martin et al., 2012). 
Catalase decomposes hydrogen peroxide into oxygen 
and water. Catalase activity is limited to the periplasmic 
space, where together with Cu-Zn SOD leave external 
sources of ROI unchanged (Kim et al., 2000). Catalase 
is not necessary virulence factor, the other enzymes can 
compensate lack of this enzyme in catalase mutants, e.g. 
alkyl hydroperoxide reductase or enzymes involved in 
DNA repair mechanisms (Seleem et al., 2008). Catalase 
is encoded by a sequence similar to katE gene of Esche­
richia coli. B. abortus, B. melitensis and B. suis catalase 
production is regulated by an increased external level 
of H2O2 (Gee et al., 2004).
Cyclic β-1-2-glucans (CβG). Brucella CβG belongs 
to II OPGs (Osmoregulated periplasmic glucans) fam-
ily (Bohin, 2000). B. abortus CβG impacts intracellu-
lar trafficking by acting on lipid rafts on macrophage 
surface. These glucans participate in control of the 
phagosome-lysosome fusion. Mutants are destroyed 
in phagolysosome and they are not able to multiply. 
Even more, mutants treated by CβG are able to control 
vacuole maturation and lysosome fusion, so they can 
reach to the ER and replicate there (Arellano-Reynoso 
et al., 2005). 
Urease. In Brucella there are non-identical urease 
operons in two separate genomes. Urease is a metal-
loenzyme, that decomposes urea to carbonic acid and 
to ammonium form, and it results in pH increase. 
This feature enables its survival in acid environment 
(Seleem et al., 2008). In I chromosome, there are two 
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urea-operons: ure­1 and ure­2, separated by 1 Mb of 
DNA. Ure­1 and ure­2 encode structural genes: ureA, 
ureB, ureC and accessory genes: ureD, ureE, ureF, ureG 
(Mobley et al., 1995). That urease may protect Brucella 
during passage through the digestive tract (stomach), 
when the bacteria access their host through the oral 
route (Bandara et al., 2007). Urease is produced by all 
bacteria belonging to the genus Brucella but B. ovis 
(Sangari et al., 2007).
Cytochrome oxidase. Cytochrome oxidase is an 
enzyme facilitating Brucella’s survival inside the macro-
phages, where oxygen availability is limited. There are 
two operons in genome encoding two types of high 
oxygen-affinity oxidases: cytochrome cbb3-type and 
cytochrome bd (ubiquinol oxidases) oxidases. Cyto-
chrome cbb3 oxidase is expressed in vitro and allows 
for colonization of anoxic tissues (maximal action in 
microaerobiosis). Cytochrome bd oxidase is expressed 
during intracellular multiplication and enables adjust-
ment to the replicative niche (Loiser-Meyer et al., 
2005), by restraining the creation of oxidative free radi-
cals and detoxification of compartment inside the cell 
(Endley et al., 2001).
Alkyl hydroperoxide reductase (AhpC, AhpD). 
These enzymes attempt protection against oxygen radi-
cal and reactive nitrogen (Chen et al., 1998). AhpC and 
ahpD are organized in an operon under one promoter 
control. AhpC mutants are more sensitive to peroxide 
killing and are vulnerable to spontaneous mutagenesis 
(DelVecchio et al., 2002; Seleem et al., 2008).
Nitric oxide reductase (NorD). Reduction of 
nitrate to dinitrogen gas is an essential process for bac-
teria in case of oxygen deficiency inside the cell; this 
process allows for respiration of nitrate (Stevanin et al., 
2005). The infected macrophages produce nitric oxide 
(NO), and Brucella can use it for own purposes. Brucella 
NorD consists of four types of reductases: Nir – nitrite 
reductase, Nar – nitrate reductase, Nor – nitric oxide 
reductase and Nos – nitrous oxide reductase, called 
the nitrification island. Possibility concerning produc-
tions of this enzymes helps to protect Brucella against 
low-oxygen conditions inside macrophages (Seleem 
et al., 2008). 
Brucella virulence factor A (BvfA). Periplasmic 
protein that occurs only in genus Brucella; there are no 
homologous sequences in Gen Bank. The bvfA expres-
sion is induced in macrophages, through phagosome 
acidification. Presumably this protein is involved in 
forming the replication intracellular niche. BvfA func-
tion is not precisely identified (Lavigne et al., 2005).
Base excision repair (BER). XthA gene encodes 
exonuclease III, which takes part in the base excision 
repair of DNA. Two different sequences of xthA occur 
in the Brucella genome: xthA­1 and xthA­2. XthA­1 
mutants exhibit increased sensitivity to reactive oxygen 
species (ROS), so this enzyme is responsible for protec-
tion against oxidative destruction (Seleem et al., 2008).
BvrR/BvrS system. The analysis of Brucella genomic 
library has confirmed an occurrence of two open reading 
frames: bvrR and bvrS. The bvrR encodes BvrR proteins 
(237 amino acid) and bvrS encodes BvrS (601 amino 
acid). There are two potential promoters (–10 and 
35 seq. located 50 bp upstream ORF of bvrR), and 
ribosome-binding sequence (9 bp upstream of the first 
codon) (Sola-Landa et al., 1998). BvrR exhibits resem-
blance to response regulators proteins, as N-terminal 
domain is composed of highly conserved aminoacids: 
aspartic (pos: 14, 15, 58) and lysine (pos: 107). C-termi-
nal domain showed high similarity sequence to OmpR 
family; therefore, this protein can be included as part of 
this family (Mizuno and Tanaka, 1997; Martínez-Nūñez 
et al., 2010). The protein is composed of three highly 
conserved domains: N-terminal sensing, periplasmic 
domain together with transmembrane component, cyto-
plasmic domain with distinctive histidine residue and 
C-terminal ATP-binding domain (Viadas et al., 2010). 
BvrS includes four highly conserved regions on C-ter-
minal domain: H, N, D/F, and G. This feature causes 
BvrS homologous to sensor proteins of the histidine pro-
tein kinase family (Stock et al., 1995). BvrS is located 
in the cell membrane (Martínez-Nūñez et al., 2010). 
Brucella BvrR/BvrS are the best characterized compo-
nents of the virulence system; mutants are incapable of 
invasion, prevention phagosome-lysosome fusion and 
intracellular replication. BvrR/BvrS system is a regula-
tor of expression of multiple genes (Viadas et al., 2010). 
These proteins affect the transcription of the membrane 
proteins: Omp3b (Omp22) or Omp3a (Omp25a) and 
have the influence on other non-protein membrane 
molecules and hence on functional and structural mem-
brane homeostasis (Manterola et al., 2007). BvrR/bvrS 
mutants show structural changes in LPS, but O-chains 
seem to be undisturbed. These mutants are incapable of 
activation of GTPase (Cdc42) before entry into the cell, 
so they persist extracellularly and in consequence they 
do not infect the cell (Guzmán-Verri et al., 2001). BvrR/
BvrS is also responsible for limited lysosome fusion and 
intracellular trafficking (López-Goñi et al., 2002).
Brucella BvrR/BvrS regulatory system action acti-
vate sensor domain of the BvrS protein by environmen-
tal signals through kinase activity. Additionally, BvrS 
causes phosphorylation and activation of BvrR protein. 
BvrR activates transcription of omp3a, omp3b and other 
genes responsible for lipid A structure and perhaps core 
of LPS. In consequence, bvrS/bvrR mutants are more 
sensitive to cationic peptides and display increased 
permeability for surfactants (López-Goñi et al., 2002; 
Seleem et al., 2008). The influence of Omp3a and 
Omp3b on virulence remains unexplained in details 
(Manterola et al., 2007).
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It has been proven that BvrR/BvrS two-component 
system regulate the expression of virB by positive 
stimulation of vjbR transcription. VjbR transcriptional 
factor interacts with virB promoter (Martínez-Nūñez 
et al., 2002).
Role of virulence factors in chronic persistence. 
Evading an immunological response to Brucella anti-
gens depends on LPS structure. The appearance of 
elongated fatty acid on the lipid A (Brucella-C28 com-
pared to others Enterobacteriaceae C12 – C16) leads 
to poor activation of TLR4 (Tool-like receptor 4) 
(de Figueiredo et al., 2015; Byndloss and Tsolis, 
2016). The other feature of Brucella spp. LPS is core 
oligosaccharide glycosylation pattern that prevents 
a connection of the bacteria with TLR4 (co-receptor 
MD-2) (Byndloss and Tsolis, 2016). Toll-like recep-
tors, the transmembrane proteins, act as PRRs (Pattern 
recognition receptors) and initiate the innate immune 
responses. TLRs are responsible for the recognition 
of components of microorganism (Uemattsu et al., 
2008). The TLR protein is composed of two domains: 
extracellular domain that is rich in leucine repeats 
and it is responsible for recognition of microbial 
components, and cytoplasmic domain – TIR, involved 
in signal transmission, activation of intermediate 
proteins and finally an activation of NF-ĸβ and 
cytokines (Radhakrishnan et al., 2009). TLR5 detects 
flagellin, but flagellin in Brucella spp. can avoid inter-
action with TLR5 as it lacks the domain recognized 
by TLR. (Andersen-Nissen et al., 2005; Kim, 2015). 
Brucella encoded TcpB/BtpA protein that acts as a fol-
lowing virulence factor (TcpB – B. melitensis, Btp1/
BtpA – B. abortus). Three pathogenic microorgan-
ism can produce similar proteins: Salmonella spp., 
E. coli and Brucella (Radhakrishnan et al., 2009). These 
proteins contain TIR domain and show similarity to 
TIRAP (MAL) – a TLR adaptor protein. TcpB promotes 
a degradation of TIRAP and disrupts TLR4 signalling 
that result in inhibition of proinflammatory cytokines 
production and dendritic cell maturation (Newman 
et al., 2006; Oliveira et al., 2008; Radhakrishnan et al., 
2009; Sengupta et al., 2010; Byndloss and Tsolis, 2016). 
TIRAP triggers recruitment of MyD88 and hence 
mediates TLR4 and TLR2 signalling (Kagan and 
Medzhitov, 2006). It seems to be likely that TcpB is able 
to interact with Death Domain of MyD88 and affect the 
signalling pathway (Chaudhary et al., 2012). Another 
group of researchers has proven that Brucella encodes 
another TIR domain-containing protein, called BtpB 
(present in all Brucella strains). This protein reacts with 
MyD88, inhibits TLR signalling, and disrupts activation 
of dendritic cells BtpB, restraining TLR2, TLR4, TLR5 
and TLR9 signalling; and together with BtpA affects DC 
maturation and inflects host inflammatory responses 
(Salcedo et al., 2013).
B. abortus has proline racemase and thus is able to 
produce anti-inflammatory cytokine IL-10. This cyto-
kine modulates macrophage activity during early phase 
of infection and leads to persistence and long-term 
survival of microorganism inside host cells (Byndloss 
and Tsolis, 2016).
Role of virulence factors in reproductive dis-
ease. The investigations performed on bovine placen-
tal explants have proven that in early infection with 
B. aborus the suppression of proinflammatory cytokines 
occured. This process is dependent on BtpB and T4SS 
proteins (use of mutants of the virB and btpB genes 
results in the reverse effect by enhancement of the pro-
inflammatory cytokines production) (Mol et al., 2014). 
In later phases, 12 h after infection with B. abortus, 
stimulation of proinflammatory cytokines and CXC 
chemokines production – CXCL6 (GCP-2) and CXCL8 
(interleukin 8) takes place. CXCL6 and IL-8 known as 
neutrophil chemoattractants cause neutrophil influx and 
have been reported to cause necrotizing placentis after 
infecting a pregnant cow (Carvalho Neta et al., 2008).
Pathogenesis
Invasion to cell. The Brucella strains survive and 
multiply within both phagocytic and non-phagocytic 
cells. The main targets for this bacterium are mac-
rophages, dendritic cells and trophoblast cells. How-
ever, Brucella can also multiply within other cells, for 
example epithelioid cell (HeLa) or murine fibroblast 
(NIH3T3) (Pizarro-Cerdá et al., 2000; Celli, 2006; 
Xavier et al., 2010). Brucella translocates across the 
mucosal epithelial cells layer, where the professional 
phagocytes (macrophages and DC cells) engulf the 
bacteria. Brucella survives within non-phagocytic cells 
up to 72 hours after infection, overcomes the epithe-
lial barrier and then penetrates the phagocytic cells. 
Approximately 10% of these bacteria survive this initial 
phase. In macrophages the pathogen avoids the host 
immune response; therefore, it can multiply and spread 
to other tissues using cellular tropism. The Brucella 
strains penetrate the host cells through a zipper-like 
mechanism (Gorvel and Moreno, 2002; de Figureido 
et al., 2015). Bacteria can spread in a host through the 
lymph nodes and then translocate to the preferred tis-
sues in reproductive tract (Kim, 2015). There, Brucella 
induces acute or chronic infection of reproductive tract 
that leads to abortion or severe reproductive tract dis-
eases. (He, 2012).
The non-opsonized Brucella organisms are inter-
nalized through lectin or fibronectin receptors but 
opsonized by complement and Fc receptors. The 
opsonized bacteria are more prone to be destroyed 
within macrophages than non-opsonized ones. The 
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pathogen binds to receptors containing of sulfated 
residues and sialic acid on surfaces of epithelial cells 
(de Figureido et al., 2015). 
Penetration into the epithelial cell requires actin 
polymerization (Kim, 2015). The adhesion of B. abortus 
to the cell surface leads to activation of GTPases of Rho 
subfamily, e.g. Rho, Rac, and Cdc42 (Guzmán-Verri 
et al., 2001). These proteins are involved in cytoskel-
etal regulation and have an impact on parasitic bacte-
rial internalization. Cdc42 is the only GTPase activated 
directly by B. abortus during the contact with a non-
phagocytic cell. It seems that other GTP-ases (Rho or 
Rac) are activated indirectly, because their inhibition 
impede invasion into host cells (Waterman-Storer et al., 
1999). Other protein acting as second messengers, i.e. 
cGMP, PIP3-kinase, MAP-kinase and tyrosine kinase 
are involved in adhesion of bacteria to the host cell sur-
face (Guzmán-Verri et al., 2001). 
Adhesion to macrophage surface is also associated 
with small GTPases activation (Guzmán-Verri et al., 
2001) and F-actin polymerization (transient and rapid 
F-actin accumulation). In the early stages of adhesion 
Annexin I is also involved, a protein that is impli-
cated in membrane fusion (Kusumawati et al., 2000). 
Bacterial internalization occurs also by the lipid rafts 
–  microdomains that occur in the macrophage cell 
membrane. These structure contribute to intracellu-
lar trafficking of Brucella (Fig.1) (Xavier et al., 2010). 
Non-opsonized Brucella strains internalize in human 
monocytes and murine macrophages by lipid rafts. This 
process requires activation of TLR4 and PI3-kinase. 
However, this process in human dendritic cells is only 
partly dependent on lipid rafts (von Bargen et al., 2012). 
Brucella strains with lack of O-polysaccharides in LPS 
(R-LPS) do not penetrate eukaryotic cells by lipid rafts, 
and thus are exterminated by macrophages (Porte 
et al., 2003; Gomez et al., 2013). Lipid rafts are rich in 
cholesterol, GPI (glycosylphosphatidylinositol) and 
GM1 (gangliosides) (Brown and London, 1998). Lipid 
rafts-associated proteins: GPI and GM1 as well as cho-
lesterol inosculate with Brucella-contain macropino-
somes and facilitate internalization with macrophage 
(Naroeni and Porte, 2002).
Brucella can be recognized by TLRs, but owing to 
modifications its interaction with TLRs is 10-fold lesser 
than for Enterobacteria. Hence, the activation of NF-κβ 
and production of inflammatory cytokines is weaker 
(de Figureido et al., 2015).
Intracellular trafficking. It has been supposed 
that intracellular trafficking is not essentially differ-
ent in professional and non-professional phagocytes 
(Gorvel and Moreno, 2002). After several minutes of 
invasion, the bacteria interact with early endosomal 
network-related compartment – early BCV – Bru­
Fig. 1. Mammalian cell invasion and intracellular trafficking.
Smooth Brucella invasion into a cell by lipid rafts and acquisition of Rab5 and EEA1 markers – early BCV. β-1,2-glucans present in mature BCV and 
modification of lipid rafts. Then, the transient BCV interacts with lysosomes, T4SS is activated and it regulates intracellular trafficking from auto-
phagosome to endoplasmatic reticulum (BCV acquires LAMP1 and Sec61β markers – late BCV – occurs only in epithelial cells). BCV acquires the 
endoplasmic reticulum markers (calnexin, calreticulin and Sec61-β) and the Brucella replicates. Rough Brucella organisms do not penetrate cell by 
lipid rafts, and therefore is exterminated.
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cella Containing Vacuole. This compartment is char-
acterized by Rab5 (GTP-binding protein) and EEA1 
(early endosomal antigen 1) markers (Pizarro-Cerdá 
et al., 1998; Pizarro-Cerdá et al., 2000). β-1,2-glucans 
are necessary for the regulation of BCV maturation in 
macrophages as well as in epithelial cells. Additional 
function of β-1,2-glucan is the modification of rich 
in cholesterol lipid rafts, which are located on BCV 
membrane surface (Arellano-Reynoso et al., 2005). 
The interaction with early endocytic network last about 
10 minutes (Pizarro-Cerdá et al., 1998). At this stage, 
acidification of BCV takes place leading to changes on 
the bacterial genes expression and enabling intracellu-
lar survival (Carvalho Neta et al., 2010). BCV does not 
interact with late endosome and it avoids fusion with 
lysosomes (by β-glucans and LPS occurrence) (Gorvel 
and Moreno, 2002; Celli, 2006). However, early BCV is 
transformed to intermediate BCV that is LAMP1 and 
Rab-7 marked (late endosomal/lysosomal markers), 
indicating that interactions with late endosomal com-
partments and lysosomes become necessary. What is 
more, in this step BCV acquires also Rab-interacting 
lysosomal protein (RILP) that is Rab-7 effector (Starr 
et al., 2008; von Bargen et al., 2012; Gomez et al., 2013). 
The interaction between BCV and late endosomes/lys-
osomes is transitional and controlled. This event allows 
for acidification of BCV and expression of acidic-con-
tingent bacterial factors, e.g., virB; simultaneously, the 
cathepsin D action does not take place (Boschiroli et al., 
2001; Starr et al., 2008; von Bargen et al., 2012). Bru­
cella type IV secretion (T4SS encoded by virB operon) 
is responsible for regulation of intracellular trafficking 
from autophagosome to endoplasmatic reticulum (ER) 
(Fig.1) (Gorvel and Moreno, 2002).
 About 1 hour after internalization, Brucella organ-
isms are located within multimembranous autopha-
gosome with LAMP1 and Sec61β (calreculin). This 
structure is also called as a late BCV and occurs only 
in epithelial cells (Pizarro-Cerdá et al., 1998). LAMP1 
function is not accurately described; however, it presum-
ably participates in the pathogen intracellular survival 
(Gorvel and Moreno, 2002). The final step of Brucella 
intercellular trafficking is an acquisition of the markers 
characteristic of the endoplasmic reticulum: calnexin, 
calreticulin and Sec61β, although in this step BCV lose 
the LAMP-1 (Pizarro-Cerdá et al., 1998). However, this 
protein is constantly present in large vacuole only in 
human monocytes, in which opsonized Brucella mul-
tiply (Bellaire et al., 2005). ER is the only compartment 
that is suitable for Brucella replication (Pizarro-Cerdá 
et al., 1998). The mechanism of BCV-ER connection 
remains unclear. In this process there are involved small 
GTPases Rab2, GAPDH – glyceraldehyde-3-phosphate 
dehydrogenase, the COPI complex (Coat Protein Com-
plex I) and protein kinase C (PKCI). COPI and PKCI 
control vesicular trafficking to the ER from Golgi. 
GAPDH/COPI/Rab2/PKCI complex is responsible for 
Brucella replication within the ER (Fugier et al., 2009).
Treatment of brucellosis
Currently, there are no effective vaccines for human, 
although several Brucella vaccines are accessible for 
livestock. Live, attenuated vaccines bereft of viru-
lence factors, still present residual virulence (e.g., Live 
B. abortus vaccine strain 19, Live B. abortus vaccine 
strain RB51, Live B. melitensis vaccine strain Rev-1). 
Subunit vaccines are proven to be relatively safe and 
they raise less concerns compared to live vaccines. They 
do not cause infection, as they present purified proteins 
or DNA to stimulate immune response. Researchers are 
still working on the improvement in livestock vaccines 
and their application in preventing human infections 
(Yang et al., 2013).
To implement a successful treatment against brucel-
losis, antibiotics penetrating into macrophages as well 
as active in acidic environment are essential (Ranjbar, 
2015). Brucellosis is a disease, that rarely leads to death 
and responds well to diverse therapeutic strategies 
(Solís et al., 2015). However, single-antibiotics therapy 
is inadequate in brucellosis, as it leads to relapse of dis-
ease (Pappas et al., 2006). Similarly, the therapy with 
single agent like: oxytetracycline, rifampin or doxycy-
cline, causes high rate of relapses (9–25%) and prolon-
gation of therapy does not provide satisfying effects. 
The treatment with trimethoprim-sulfamethoxazole or 
ciprofloxacin results in relapse in 30% and 83% of cases, 
respectively (Ranjbar, 2015). Treatment should prevent 
relapse of disease, further complications (arthritis, 
spondylitis, sacroilitis etc.) and enable quick relief of 
symptoms. The combination of two antibiotics in the-
rapy of infections caused by Brucella is more effective 
than monotherapy. The WHO in 1986 recommended 
doxycycline with rifampicin for six weeks, replaced with 
tetracycline in combination with streptomycin. Cur-
rently, the combinations of other antibiotics or chemo-
therapeutics in therapy of brucellosis are used, such as 
fluoroquinolones or co-trimoxazole with rifampicin, 
doxycycline-streptomycin and doxycycline-rifampicin 
(Skalsky et al., 2008). During the treatment of brucel-
losis with streptomycin and doxycycline (SD), a failure 
of treatment and relapse rates at 7.4% and 4.8%, respec-
tively were noted. Almost similar results of therapy were 
observed during therapy with doxycycline and rifampin 
(DR) or streptomycin together with tetracycline (ST); 
however, their relapse rates were higher than in SD 
treatment. Another dual therapies of brucellosis are 
known, for example doxycycline and gentamicin (DG) 
with the average failure rate of 5.2% and the relapse rate 
Głowacka P. et al. 2158
of 5.9%, or cotrimoxazole and rifampicin (RCTM) used 
in children brucellosis with the failure of treatment and 
relapse rates at 0–16.4% and 3.1–10%, respectively. The 
treatment with ciprofloxacin or ofloxacin with doxy-
cycline, cotrimoxazole, rifampicin brought about the 
relapse rate between 3.2 to 26% (average 11.4%) and 
the failure rate between 3.2% to 26% (12.2%) (Alavi 
and Alavi, 2013). There were three clinical trials that 
used triple-drug therapy with doxycycline, rifampicin 
and aminoglycoside. There is no clear evidence on the 
superiority of triple-drug therapy when compared 
to the two-drug therapy. Nevertheless, it seems that 
triple-drug therapy is more effective in preventing 
relapses, but less successful in short-term treatment 
than two-drug therapy (Solís et al., 2015). The research 
by Alavi and Alavi (2013) suggested triple therapy for 
eight weeks in complicated cases (with spondylitis, or 
arthritis) due to lower treatment failure rates than two-
drug therapy. Doxycycline and aminoglycoside therapy 
is recommended in uncomplicated chronic, or acute 
cases and in complicated cases without endocarditis, 
spondylitis, arthritis. In uncomplicated cases, strepto-
mycin and doxycycline, or gentamicin are also advo-
cated (Alavi and Alavi, 2013). 
Smith and colleagues (2013) found a new strategy to 
treat brucellosis. The connection of BCV with the ER 
requires remodeling of endoplasmatic reticulum, which 
is necessary in modification of the ER structure during 
host stress response, which is called the Unfolded Pro-
tein Response (UPR). The disruption of UPR, through 
tauroursodeoxycholic acid drug can inhibit Brucella 
replication. UPR can be a novel target in the of brucel-
losis (Smith et al., 2013). 
There are studies concerning the influence of gin-
seng saponin fraction A (RGSF-A) for combating bru-
cellosis. Ginseng is a valued plant in Asia, considered 
a panacea to variety range of diseases. Arayan et al. 
(2015) examined the influence of RGSF-A for eradica-
tion of bacterial infection in RAW 264.7 cells. In this 
study, the bacterial internalization and adhesion were 
reduced in the cells treated when compared to the 
control cells without treatment. RGSF-A takes part in 
downregulation of MAPKs (mitogen-activated protein 
kinases) and hence, limits polymerization of F-actin 
and inhibits bacterial penetration into the cells. RGSF-
A influences also intracellular trafficking of B. abor­
tus and favors interaction of B. abortus-containing 
phagosomes (BCPs) with LAMP-1. LAMP-1 is trans-
membrane protein, that is responsible for the fusion 
of lysosomes with phagosomes, enabling the connec-
tion of BCPs with lysosome and elimination of bacte-
ria (Arayan et al., 2015; Reyes et al., 2016; Huy et al., 
2017). Huy et al. (2017) have proven that ginsenoside 
Rg3 – panaxadiol saponin components of RGSF-A have 
been the major factor controlling brucellosis. 
Undoubtedly, there are also other promising herbal 
plants e.g. Teucrium polium, Scophularia deserti, Alhagi, 
Eucalyptus, garlic and roots of barberry that contain 
bioactive ingredients (flavones, flavonoids, anthocya-
nins and tanins) that can be effecive in preventing or 
even combat brucellosis (Naghadi et al., 2016). 
Conclusions
Brucella is an intracellular pathogen, especially 
dangerous for domestic animals, which causes mas-
sive infections and thus significant economic losses. 
Moreover, people who work with infected animals 
comprise a risk group, e.g., farmers, veterinarians, or 
laboratorians and they are most endangered of being 
exposed to the pathogen. Brucellosis in human causes 
non-specific symptoms, therefore no plausible estima-
tion can be managed to detect the number of infected 
people. Brucella is an inquisitive etiological agent, as 
does not produce classical virulence factors. The pro-
cess of infection is a complex one, and there are many 
unexplained issues associated with it. Therefore, further 
studies of infection mechanisms are required. 
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